BioCryst Pharmaceuticals (BCRX) 10-Q2013 Q1 Quarterly report

Filed: 9 May 13, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: acute, Army, bioavailability, broad, BSAV, burdensome, Cambridge, cancer, chemical, chronic, CINRYZE, composition, constriction, content, core, deny, denying, dosage, dose, doubling, Ebola, entirety, essential, fever, fiscal, flexibility, formal, GSK, HAE, half, hemorrhagic, host, image, imperiled, instability, intravenously, IPR, line, lymphoma, Marburg, maximize, metabolism, mg, moderate, multicenter, multinational, Munidpharma, ninety, notification, ORR, path, pathway, peripheral, political, pose, pressure, proper, question, referenced, regimen, remittance, remitted, renal, repeated, retrospective, select, selective, SOC, space, spectrum, spread, submission, succeed, summer, supplier, synergistic, threat, uncomplicated, undergone, unstable, upstream, USAMRIID, vacant, ViroPharma, virulent, wind, window, written, yellow

Removed: advice, analog, autoimmune, beneficially, Biota, blinded, ceased, certificate, charge, CLL, conform, creation, dating, decided, declare, declining, determination, divided, EMA, error, exempt, feedback, FIFO, GlaxoSmithKline, grow, healthy, immune, improvidently, incorporation, inducement, insight, interference, labor, leading, lieu, limitation, lt, mediated, newly, observed, opportunistic, opportunity, originally, partial, paying, planning, plc, priority, prophylactic, provoke, quantification, recognizing, recruit, reliant, remedy, repurchased, responding, RNA, shipping, spoilage, suggestion, targeting, tolerated, track, transition, unmarketable, unusual, variability, withholding, XO

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

BCRX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of BioCryst Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Thomas R. Staab, II, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Thomas R. Staab, II

Thomas R. Staab, II

Senior Vice President, Chief Financial Officer and Treasurer

Date: May 9, 2013